{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T07:07:22Z","timestamp":1765955242328,"version":"3.48.0"},"reference-count":128,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Funct Integr Genomics"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s10142-025-01778-9","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T05:24:51Z","timestamp":1765949091000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Overcoming barriers in CAR-NK immunotherapy: CRISPR-Driven advances in checkpoint editing and allogeneic design"],"prefix":"10.1007","volume":"26","author":[{"given":"Mohammed J.","family":"Mansoor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah F.","family":"Al-Taie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zahraa Abbas","family":"Al-Khafaji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali G.","family":"Alkhathami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jyothi S.","family":"Renuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8606-3961","authenticated-orcid":false,"given":"Rajashree","family":"Panigrahi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hansi","family":"Negi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pushkar","family":"Jassal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0926-7428","authenticated-orcid":false,"given":"Yasser Fakri","family":"Mustafa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamza Fadhel","family":"Hamzah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"issue":"2","key":"1778_CR78","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/imm.13094","volume":"158","author":"LO Afolabi","year":"2019","unstructured":"Afolabi LO, Adeshakin AO, Sani MM, Bi J, Wan X (2019) Genetic reprogramming for NK cell cancer immunotherapy with CRISPR\/Cas9. Immunology 158(2):63\u201369","journal-title":"Immunology"},{"key":"1778_CR13","doi-asserted-by":"crossref","unstructured":"Albinger N, Bexte T, Buchinger L, Wendel P, Al-Ajami A, Gessner A, S\u00e4rchen V, Alzubi J, Mertlitz S, Penack O (2022) CRISPR\/Cas9 gene editing of immune checkpoint receptor NKG2A improves the efficacy of primary CD33-CAR-NK cells against AML. In.: American Society of Hematology Washington, DC","DOI":"10.1182\/blood-2022-169758"},{"issue":"8","key":"1778_CR87","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/s41590-020-0728-z","volume":"21","author":"T Bald","year":"2020","unstructured":"Bald T, Krummel MF, Smyth MJ, Barry KC (2020) The NK cell\u2013cancer cycle: advances and new challenges in NK cell\u2013based immunotherapies. Nat Immunol 21(8):835\u2013847","journal-title":"Nat Immunol"},{"issue":"7","key":"1778_CR38","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/j.ccell.2022.06.001","volume":"40","author":"JA Belk","year":"2022","unstructured":"Belk JA, Yao W, Ly N, Freitas KA, Chen YT, Shi Q, Valencia AM, Shifrut E, Kale N, Yost KE et al (2022) Genome-wide CRISPR screens of T cell exhaustion identify chromatin remodeling factors that limit T cell persistence. Cancer Cell 40(7):768\u2013786e767","journal-title":"Cancer Cell"},{"issue":"8","key":"1778_CR42","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1182\/blood.2022016200","volume":"141","author":"MM Berrien-Elliott","year":"2023","unstructured":"Berrien-Elliott MM, Jacobs MT, Fehniger TA (2023) Allogeneic natural killer cell therapy. Blood 141(8):856\u2013868","journal-title":"Blood"},{"issue":"1","key":"1778_CR72","doi-asserted-by":"publisher","first-page":"8439","DOI":"10.1038\/s41467-024-52388-1","volume":"15","author":"T Bexte","year":"2024","unstructured":"Bexte T, Albinger N, Al Ajami A, Wendel P, Buchinger L, Gessner A, Alzubi J, S\u00e4rchen V, Vogler M, Rasheed HM (2024) CRISPR\/Cas9 editing of NKG2A improves the efficacy of primary CD33-directed chimeric antigen receptor natural killer cells. Nat Commun 15(1):8439","journal-title":"Nat Commun"},{"key":"1778_CR98","doi-asserted-by":"publisher","DOI":"10.1101\/2024.01.26.577405","author":"R Biondo","year":"2024","unstructured":"Biondo R, Nayak I, M\u00f6ker N, Zhang C, Stewart WC, Khakoo S, Das J (2024) Impact of IL-21 on natural killer cell proliferation and function - a mathematical and functional assessment. bioRxiv. https:\/\/doi.org\/10.1101\/2024.01.26.577405","journal-title":"bioRxiv"},{"issue":"6","key":"1778_CR27","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s10142-024-01486-w","volume":"24","author":"A Borah","year":"2024","unstructured":"Borah A, Singh S, Chattopadhyay R, Kaur J, Bari VK (2024) Integration of CRISPR\/Cas9 with multi-omics technologies to engineer secondary metabolite productions in medicinal plant: challenges and prospects. Funct Integr Genom 24(6):207","journal-title":"Funct Integr Genom"},{"issue":"5","key":"1778_CR18","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.it.2021.03.003","volume":"42","author":"FA Buquicchio","year":"2021","unstructured":"Buquicchio FA, Satpathy AT (2021) Interrogating immune cells and cancer with CRISPR-Cas9. Trends Immunol 42(5):432\u2013446","journal-title":"Trends Immunol"},{"issue":"12","key":"1778_CR21","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1007\/s11427-023-2571-0","volume":"67","author":"Y Cao","year":"2024","unstructured":"Cao Y, Li X, Pan Y, Wang H, Yang S, Hong L, Ye L (2024) CRISPR-based genetic screens advance cancer immunology. Sci China Life Sci 67(12):2554\u20132562","journal-title":"Sci China Life Sci"},{"key":"1778_CR17","doi-asserted-by":"crossref","unstructured":"Castellano E, Garc\u00eda-Ortiz A, Ugalde L, Maroto Martin E, Encinas Mayoral J, Oliva R, Garcia-Garcia L, Pe\u00f1a I, \u00c1lvarez N, Carre\u00f1o G (2024) CRISPR\/Cas9 Multi-Editing enhances CAR NK cells therapeutic potential against multiple myeloma. In.: American Society of Hematology Washington, DC","DOI":"10.1182\/blood-2024-207942"},{"key":"1778_CR71","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15041264","author":"V Cazzetta","year":"2023","unstructured":"Cazzetta V, Depierreux D, Colucci F, Mikulak J, Mavilio D (2023) NKG2A immune checkpoint in V\u03b42 T cells: emerging application in cancer immunotherapy. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers15041264","journal-title":"Cancers (Basel)"},{"key":"1778_CR108","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10040804","author":"LY Chan","year":"2022","unstructured":"Chan LY, Dass SA, Tye GJ, Imran SAM, Wan Kamarul Zaman WS, Nordin F (2022) CAR-T cells\/-NK cells in cancer immunotherapy and the potential of MSC to enhance its efficacy: a review. Biomedicines. https:\/\/doi.org\/10.3390\/biomedicines10040804","journal-title":"Biomedicines"},{"issue":"3","key":"1778_CR23","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1093\/bfgp\/elaa001","volume":"19","author":"X Cheng","year":"2020","unstructured":"Cheng X, Fan S, Wen C, Du X (2020) CRISPR\/Cas9 for cancer treatment: technology, clinical applications and challenges. Brief Funct Genomics 19(3):209\u2013214","journal-title":"Brief Funct Genomics"},{"key":"1778_CR65","doi-asserted-by":"publisher","first-page":"6829","DOI":"10.1182\/blood-2023-182516","volume":"142","author":"H Chen","year":"2023","unstructured":"Chen H, He B, Zhong S, Huang D, Deng S, Liu Q, Li C, Huang L, Xu N (2023) Disruption of SOCS1 promotes the antitumor activity of CD19-specific CAR NK cells coexpressing IL-15. Blood 142:6829","journal-title":"Blood"},{"key":"1778_CR22","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.canlet.2019.01.017","volume":"447","author":"M Chen","year":"2019","unstructured":"Chen M, Mao A, Xu M, Weng Q, Mao J, Ji J (2019) CRISPR-Cas9 for cancer therapy: opportunities and challenges. Cancer Lett 447:48\u201355","journal-title":"Cancer Lett"},{"key":"1778_CR61","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1182\/blood-2021-148649","volume":"138","author":"E Choi","year":"2021","unstructured":"Choi E, Chang J-W, Krueger J, Lahr WS, Pomeroy E, Walsh M, Khamhoung A, Johnson J, Franco C, Swiech L (2021) Engineering CD70-directed CAR-NK cells for the treatment of hematological and solid malignancies. Blood 138:1691","journal-title":"Blood"},{"issue":"5","key":"1778_CR24","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.trecan.2018.03.002","volume":"4","author":"RD Chow","year":"2018","unstructured":"Chow RD, Chen S (2018) Cancer CRISPR screens in vivo. Trends Cancer 4(5):349\u2013358","journal-title":"Trends Cancer"},{"issue":"5","key":"1778_CR99","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.4049\/jimmunol.178.5.2827","volume":"178","author":"JM Coquet","year":"2007","unstructured":"Coquet JM, Kyparissoudis K, Pellicci DG, Besra G, Berzins SP, Smyth MJ, Godfrey DI (2007) IL-21 is produced by NKT cells and modulates NKT cell activation and cytokine production. J Immunol 178(5):2827\u20132834","journal-title":"J Immunol"},{"issue":"1","key":"1778_CR69","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s40425-019-0553-9","volume":"7","author":"T Courau","year":"2019","unstructured":"Courau T, Bonnereau J, Chicoteau J, Bottois H, Remark R, Assante Miranda L, Toubert A, Blery M, Aparicio T, Allez M et al (2019) Cocultures of human colorectal tumor spheroids with immune cells reveal the therapeutic potential of MICA\/B and NKG2A targeting for cancer treatment. J Immunother Cancer 7(1):74","journal-title":"J Immunother Cancer"},{"issue":"12","key":"1778_CR47","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1038\/s41590-023-01659-y","volume":"24","author":"OK Dagher","year":"2023","unstructured":"Dagher OK, Posey AD Jr. (2023) Forks in the road for CAR T and CAR NK cell cancer therapies. Nat Immunol 24(12):1994\u20132007","journal-title":"Nat Immunol"},{"issue":"5","key":"1778_CR58","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1182\/blood.2020007748","volume":"137","author":"M Daher","year":"2021","unstructured":"Daher M, Basar R, Gokdemir E, Baran N, Uprety N, Nunez Cortes AK, Mendt M, Kerbauy LN, Banerjee PP, Shanley M et al (2021) Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells. Blood 137(5):624\u2013636","journal-title":"Blood"},{"issue":"4","key":"1778_CR52","doi-asserted-by":"publisher","first-page":"e1274","DOI":"10.1002\/cti2.1274","volume":"10","author":"M Daher","year":"2021","unstructured":"Daher M, Melo Garcia L, Li Y, Rezvani K (2021) CAR-NK cells: the next wave of cellular therapy for cancer. Clin Translational Immunol 10(4):e1274","journal-title":"Clin Translational Immunol"},{"issue":"2","key":"1778_CR60","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/s41417-025-00872-1","volume":"32","author":"L Dai","year":"2025","unstructured":"Dai L, Zhang P, Niu X, Peng X, Suleiman RB, Zhang G, Wan X (2025) CRISPR knock-in of a chimeric antigen receptor into GAPDH 3\u2019UTR locus generates potent B7H3-specific NK-92MI cells. Cancer Gene Ther 32(2):227\u2013239","journal-title":"Cancer Gene Ther"},{"issue":"7","key":"1778_CR25","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1016\/j.cell.2022.02.015","volume":"185","author":"M Dhainaut","year":"2022","unstructured":"Dhainaut M, Rose SA, Akturk G, Wroblewska A, Nielsen SR, Park ES, Buckup M, Roudko V, Pia L, Sweeney R et al (2022) Spatial CRISPR genomics identifies regulators of the tumor microenvironment. Cell 185(7):1223\u20131239e1220","journal-title":"Cell"},{"key":"1778_CR123","unstructured":"Dogariu Y (2021) Assessing the effect of CRISPR\/Cas9-mediated PD-1 knock-out in cord blood-derived TCR-engineered CD8\u2009+\u2009T cells using a short-term in vitro exhaustion system"},{"issue":"10","key":"1778_CR26","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1038\/s41590-022-01315-x","volume":"23","author":"J Dubrot","year":"2022","unstructured":"Dubrot J, Du PP, Lane-Reticker SK, Kessler EA, Muscato AJ, Mehta A, Freeman SS, Allen PM, Olander KE, Ockerman KM et al (2022) In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer. Nat Immunol 23(10):1495\u20131506","journal-title":"Nat Immunol"},{"key":"1778_CR46","doi-asserted-by":"publisher","first-page":"108587","DOI":"10.1016\/j.intimp.2022.108587","volume":"106","author":"H Ebrahimiyan","year":"2022","unstructured":"Ebrahimiyan H, Tamimi A, Shokoohian B, Minaei N, Memarnejadian A, Hossein-Khannazer N, Hassan M, Vosough M (2022) Novel insights in CAR-NK cells beyond CAR-T cell technology; promising advantages. Int Immunopharmacol 106:108587","journal-title":"Int Immunopharmacol"},{"key":"1778_CR125","doi-asserted-by":"publisher","first-page":"834002","DOI":"10.3389\/fonc.2022.834002","volume":"12","author":"E Elmas","year":"2022","unstructured":"Elmas E, Saljoughian N, de Souza Fernandes Pereira M, Tullius BP, Sorathia K, Nakkula RJ, Lee DA, Naeimi Kararoudi M (2022) CRISPR gene editing of human primary NK and T cells for cancer immunotherapy. Front Oncol 12:834002","journal-title":"Front Oncol"},{"key":"1778_CR28","doi-asserted-by":"publisher","first-page":"118969","DOI":"10.1016\/j.lfs.2020.118969","volume":"267","author":"A Ghaemi","year":"2021","unstructured":"Ghaemi A, Bagheri E, Abnous K, Taghdisi SM, Ramezani M, Alibolandi M (2021) CRISPR-cas9 genome editing delivery systems for targeted cancer therapy. Life Sci 267:118969","journal-title":"Life Sci"},{"key":"1778_CR7","unstructured":"Ghanghro AW, Haq EU, Rahman A, Zahoor U, Noor A, Ishaque I (2025) CRISPR-MEDIATED CAR-NK CELL THERAPY TARGETING TUMOR-ASSOCIATED MACROPHAGES IN PEDIATRIC OSTEOSARCOMA"},{"issue":"1","key":"1778_CR48","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13045-021-01083-5","volume":"14","author":"Y Gong","year":"2021","unstructured":"Gong Y, Klein Wolterink RGJ, Wang J, Bos GMJ, Germeraad WTV (2021) Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy. J Hematol Oncol 14(1):73","journal-title":"J Hematol Oncol"},{"issue":"3","key":"1778_CR122","doi-asserted-by":"publisher","first-page":"e010699","DOI":"10.1136\/jitc-2024-010699","volume":"13","author":"S Guia","year":"2025","unstructured":"Guia S, Fenis A, De Chanville CB, Galluso J, Medjouel H, Escaliere B, Modelska A, Vienne M, Lopes N, Pouchin A (2025) Genome-wide CRISPR\/Cas9 screen reveals factors that influence the susceptibility of tumor cells to NK cell-mediated killing. J Immunother Cancer 13(3):e010699","journal-title":"J Immunother Cancer"},{"key":"1778_CR86","doi-asserted-by":"crossref","unstructured":"Guo C, Chan IH, Buren L, Fan Y, Aronov A, Trager JB (2020) CRISPR\/Cas9-gRNA RNP mediated gene knockout of TGF\u03b2R2 and CISH enhances CD19-CAR NK cell function and provides resistance to TGF\u03b2","DOI":"10.1158\/1538-7445.AM2020-891"},{"key":"1778_CR105","doi-asserted-by":"publisher","first-page":"152495","DOI":"10.1016\/j.bbrc.2025.152495","volume":"781","author":"C Guo","year":"2025","unstructured":"Guo C, Cheng S, Cui F, Qian Y, Bao Q, Sun Y, Zhi L, Niu Z, Li M, Zhu W (2025) A membrane-bound IL-2 promotes CAR-NK cell proliferation, anti-apoptosis and anti-tumor activity. Biochem Biophys Res Commun 781:152495","journal-title":"Biochem Biophys Res Commun"},{"key":"1778_CR82","first-page":"A123","volume":"9","author":"C Guo","year":"2021","unstructured":"Guo C, Fan Y, Aronov A, Buren L, Xie M-H, Chan I, Lazetic S, Trager J (2021) CISH gene-knockout anti-CD70-CAR NK cells demonstrate potent anti-tumor activity against solid tumor cell lines and provide partial resistance to tumor microenvironment Inhibition. J Immunother Cancer 9:A123","journal-title":"J Immunother Cancer"},{"issue":"7Supplement","key":"1778_CR80","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1158\/1538-7445.AM2023-890","volume":"83","author":"C Guo","year":"2023","unstructured":"Guo C, Fan Y, Aronov A, Kimura N, Juat D, Sood J, Chan IH, Trager JB (2023) ADAM17 knockout NK or CAR NK cells augment antibody dependent cellular cytotoxicity (ADCC) and anti-tumor activity. Cancer Res 83(7Supplement):890\u2013890","journal-title":"Cancer Res"},{"issue":"12Supplement","key":"1778_CR10","doi-asserted-by":"publisher","first-page":"5512","DOI":"10.1158\/1538-7445.AM2022-5512","volume":"82","author":"C Guo","year":"2022","unstructured":"Guo C, Fan Y, Aronov A, Zhang Q, Sahu S, Dequeant M-L, Guo C, Karnik S, Leary GD, Massilamany C (2022) CBLB, CISH and CD70 multiplexed gene knockout with CRISPR\/Cas9 enhances cytotoxicity of CD70-CAR NK cells and provides greater resistance to TGF-\u03b2 for cancer immunotherapy. Cancer Res 82(12Supplement):5512","journal-title":"Cancer Res"},{"issue":"11","key":"1778_CR9","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/j.jcyt.2022.07.008","volume":"24","author":"M Gurney","year":"2022","unstructured":"Gurney M, O\u2019Reilly E, Corcoran S, Brophy S, Krawczyk J, Otto NM, Hermanson DL, Childs RW, Szegezdi E, O\u2019Dwyer ME (2022) Concurrent transposon engineering and CRISPR\/Cas9 genome editing of primary CLL-1 chimeric antigen receptor-natural killer cells. Cytotherapy 24(11):1087\u20131094","journal-title":"Cytotherapy"},{"issue":"1","key":"1778_CR55","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s40164-025-00639-2","volume":"14","author":"B He","year":"2025","unstructured":"He B, Chen H, Wu J, Qiu S, Mai Q, Zeng Q, Wang C, Deng S, Cai Z, Liu X et al (2025) Interleukin-21 engineering enhances CD19-specific CAR-NK cell activity against B-cell lymphoma via enriched metabolic pathways. Experimental Hematol Oncol 14(1):51","journal-title":"Experimental Hematol Oncol"},{"key":"1778_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-025-01407-7","author":"JD Hebert","year":"2025","unstructured":"Hebert JD, Xu H, Tang YJ, Ruiz PA, Detrick CR, Wang J, Hughes NW, Donosa O, Siah VP, Andrejka L (2025) Efficient and multiplexed somatic genome editing with Cas12a mice. Nat Biomed Eng. https:\/\/doi.org\/10.1038\/s41551-025-01407-7","journal-title":"Nat Biomed Eng"},{"issue":"2","key":"1778_CR20","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s10142-024-01314-1","volume":"24","author":"D Hwarari","year":"2024","unstructured":"Hwarari D, Radani Y, Ke Y, Chen J, Yang L (2024) CRISPR\/Cas genome editing in plants: mechanisms, applications, and overcoming bottlenecks. Funct Integr Genom 24(2):50","journal-title":"Funct Integr Genom"},{"issue":"11","key":"1778_CR96","doi-asserted-by":"publisher","first-page":"e70040","DOI":"10.1002\/cpz1.70040","volume":"4","author":"T Ingegnere","year":"2024","unstructured":"Ingegnere T, Segain B, Cozzani A, Carlsten M, Mitra S, Gaggero S (2024) Optimizing CAR-NK cell transduction and expansion: leveraging cytokine modulation for enhanced performance. Curr Protoc 4(11):e70040","journal-title":"Curr Protoc"},{"key":"1778_CR103","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1182\/blood-2024-204369","volume":"144","author":"J Jang","year":"2024","unstructured":"Jang J, Stanojevic M, Piccinelli S, Sheffer M, Birch GC, Shapiro RM, Stahl M, Koreth J, Wu CJ, Soiffer RJ et al (2024) Mesothelin targeting IL12-engineered CAR memory-like NK cells demonstrate promising efficacy in acute myeloid leukemia. Blood 144:917","journal-title":"Blood"},{"issue":"3","key":"1778_CR119","doi-asserted-by":"publisher","first-page":"e0121788","DOI":"10.1371\/journal.pone.0121788","volume":"10","author":"Y Jing","year":"2015","unstructured":"Jing Y, Ni Z, Wu J, Higgins L, Markowski TW, Kaufman DS, Walcheck B (2015) Identification of an ADAM17 cleavage region in human CD16 (Fc\u03b3RIII) and the engineering of a non-cleavable version of the receptor in NK cells. PLoS One 10(3):e0121788","journal-title":"PLoS One"},{"issue":"6","key":"1778_CR15","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s00262-025-04010-6","volume":"74","author":"W J\u00fcnemann","year":"2025","unstructured":"J\u00fcnemann W, Bley I, Rekowski L, Klokow M, Herppich S, M\u00fcller I, Cornils K (2025) GD2-CAR NK-92 cell activity against neuroblastoma cells is insusceptible to TIGIT knockout. Cancer Immunol Immunother 74(6):191","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"1778_CR12","doi-asserted-by":"publisher","first-page":"384","DOI":"10.5603\/EP.2013.0022","volume":"64","author":"D Kajdaniuk","year":"2013","unstructured":"Kajdaniuk D, Marek B, Borgiel-Marek H, Kos-Kud\u0142a B (2013) Transforming growth factor beta1 (TGFbeta1) in physiology and pathology. Endokrynol Pol 64(5):384\u2013396","journal-title":"Endokrynol Pol"},{"key":"1778_CR117","doi-asserted-by":"crossref","unstructured":"Kararoudi MN, Likhite S, Elmas E, Yamamoto K, Schwartz M, Sorathia K, Pereira MSF, Sezgin Y, Devine RD, Lyberger JM (2022) Optimization and validation of CAR transduction into human primary NK cells using CRISPR and AAV. Cell Rep Methods 2(6)","DOI":"10.1016\/j.crmeth.2022.100236"},{"issue":"4","key":"1778_CR100","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/S1074-7613(02)00295-9","volume":"16","author":"MT Kasaian","year":"2002","unstructured":"Kasaian MT, Whitters MJ, Carter LL, Lowe LD, Jussif JM, Deng B, Johnson KA, Witek JS, Senices M, Konz RF et al (2002) IL-21 limits NK cell responses and promotes antigen-specific T cell activation: a mediator of the transition from innate to adaptive immunity. Immunity 16(4):559\u2013569","journal-title":"Immunity"},{"issue":"5","key":"1778_CR29","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/s41568-022-00441-w","volume":"22","author":"A Katti","year":"2022","unstructured":"Katti A, Diaz BJ, Caragine CM, Sanjana NE, Dow LE (2022) CRISPR in cancer biology and therapy. Nat Rev Cancer 22(5):259\u2013279","journal-title":"Nat Rev Cancer"},{"issue":"32","key":"1778_CR31","doi-asserted-by":"publisher","first-page":"52541","DOI":"10.18632\/oncotarget.9646","volume":"7","author":"FA Khan","year":"2016","unstructured":"Khan FA, Pandupuspitasari NS, Chun-Jie H, Ao Z, Jamal M, Zohaib A, Khan FA, Hakim MR (2016) ShuJun Z: CRISPR\/Cas9 therapeutics: a cure for cancer and other genetic diseases. Oncotarget 7(32):52541\u201352552","journal-title":"Oncotarget"},{"issue":"1","key":"1778_CR1","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1080\/14712598.2022.2154601","volume":"23","author":"S Khanmohammadi","year":"2023","unstructured":"Khanmohammadi S, Rezaei N (2023) CAR-NK cells: a promising cellular immunotherapy in lymphoma. Expert Opin Biol Ther 23(1):37\u201347","journal-title":"Expert Opin Biol Ther"},{"key":"1778_CR2","doi-asserted-by":"publisher","first-page":"707542","DOI":"10.3389\/fimmu.2021.707542","volume":"12","author":"MB Khawar","year":"2021","unstructured":"Khawar MB, Sun H (2021) CAR-NK cells: from natural basis to design for kill. Front Immunol 12:707542","journal-title":"Front Immunol"},{"key":"1778_CR70","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1146\/annurev-immunol-101921-044122","volume":"41","author":"O Kyrysyuk","year":"2023","unstructured":"Kyrysyuk O, Wucherpfennig KW (2023) Designing cancer immunotherapies that engage T cells and NK cells. Annu Rev Immunol 41:17\u201338","journal-title":"Annu Rev Immunol"},{"issue":"1","key":"1778_CR74","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1186\/s13046-023-02840-9","volume":"42","author":"DH Lee","year":"2023","unstructured":"Lee DH, Ahn H, Sim HI, Choi E, Choi S, Jo Y, Yun B, Song HK, Oh SJ, Denda-Nagai K et al (2023) A CRISPR activation screen identifies MUC-21 as critical for resistance to NK and T cell-mediated cytotoxicity. J Exp Clin Cancer Res 42(1):272","journal-title":"J Exp Clin Cancer Res"},{"key":"1778_CR75","doi-asserted-by":"publisher","first-page":"1410761","DOI":"10.3389\/fonc.2024.1410761","volume":"14","author":"M Li","year":"2024","unstructured":"Li M, Li H, Yuan T, Liu Z, Li Y, Tan Y, Long Y (2024) MUC21: a new target for tumor treatment. Front Oncol 14:1410761","journal-title":"Front Oncol"},{"key":"1778_CR3","doi-asserted-by":"publisher","first-page":"1361194","DOI":"10.3389\/fimmu.2024.1361194","volume":"15","author":"T Li","year":"2024","unstructured":"Li T, Niu M, Zhang W, Qin S, Zhou J, Yi M (2024) CAR-NK cells for cancer immunotherapy: recent advances and future directions. Front Immunol 15:1361194","journal-title":"Front Immunol"},{"key":"1778_CR97","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1182\/blood-2024-198167","volume":"144","author":"F Liu","year":"2024","unstructured":"Liu F, Tarannum M, Zhao Y, Zhang YJ, Ham JD, Lei K, Qiang Y, Deng X, Nguyen M, Khanhlinh D (2024) One-step construction of allogeneic CAR-NK cells preventing rejection and mediating enhanced anti-tumor responses. Blood 144:915","journal-title":"Blood"},{"issue":"1","key":"1778_CR43","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13045-020-01014-w","volume":"14","author":"S Liu","year":"2021","unstructured":"Liu S, Galat V, Galat Y, Lee YKA, Wainwright D, Wu J (2021) NK cell-based cancer immunotherapy: from basic biology to clinical development. J Hematol Oncol 14(1):7","journal-title":"J Hematol Oncol"},{"issue":"2","key":"1778_CR67","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.ccell.2023.01.001","volume":"41","author":"X Liu","year":"2023","unstructured":"Liu X, Song J, Zhang H, Liu X, Zuo F, Zhao Y, Zhao Y, Yin X, Guo X, Wu X et al (2023) Immune checkpoint HLA-E:CD94-NKG2A mediates evasion of Circulating tumor cells from NK cell surveillance. Cancer Cell 41(2):272\u2013287e279","journal-title":"Cancer Cell"},{"issue":"9","key":"1778_CR76","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1002\/cbin.11817","volume":"46","author":"X Liu","year":"2022","unstructured":"Liu X, Xiao Y, Xiong X, Qi X (2022) MUC21 controls melanoma progression via regulating SLITRK5 and Hedgehog signaling pathway. Cell Biol Int 46(9):1458\u20131467","journal-title":"Cell Biol Int"},{"issue":"8","key":"1778_CR114","doi-asserted-by":"publisher","first-page":"100677","DOI":"10.1016\/j.medj.2025.100677","volume":"6","author":"YR Li","year":"2025","unstructured":"Li YR, Zhu Y, Fang Y, Lyu Z, Yang L (2025) Emerging trends in clinical allogeneic CAR cell therapy. Med 6(8):100677","journal-title":"Med"},{"issue":"2","key":"1778_CR109","doi-asserted-by":"publisher","first-page":"101931","DOI":"10.1016\/j.xcrm.2025.101931","volume":"6","author":"T Look","year":"2025","unstructured":"Look T, Sankowski R, Bouzereau M, Fazio S, Sun M, Buck A, Binder N, Mastall M, Prisco F, Seehusen F et al (2025) CAR T cells, CAR NK cells, and CAR macrophages exhibit distinct traits in glioma models but are similarly enhanced when combined with cytokines. Cell Rep Med 6(2):101931","journal-title":"Cell Rep Med"},{"issue":"1","key":"1778_CR39","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s12943-022-01663-0","volume":"21","author":"J Lu","year":"2022","unstructured":"Lu J, Jiang G (2022) The journey of CAR-T therapy in hematological malignancies. Mol Cancer 21(1):194","journal-title":"Mol Cancer"},{"key":"1778_CR14","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.molimm.2017.06.025","volume":"88","author":"E Lusty","year":"2017","unstructured":"Lusty E, Poznanski SM, Kwofie K, Mandur TS, Lee DA, Richards CD, Ashkar AA (2017) IL-18\/IL-15\/IL-12 synergy induces elevated and prolonged IFN-\u03b3 production by ex vivo expanded NK cells which is not due to enhanced STAT4 activation. Mol Immunol 88:138\u2013147","journal-title":"Mol Immunol"},{"key":"1778_CR63","doi-asserted-by":"publisher","first-page":"1231916","DOI":"10.3389\/fimmu.2023.1231916","volume":"14","author":"A Mac Donald","year":"2023","unstructured":"Mac Donald A, Guipouy D, Lemieux W, Harvey M, Bordeleau LJ, Guay D, Rom\u00e9ro H, Li Y, Dion R, B\u00e9land K et al (2023) KLRC1 knockout overcomes HLA-E-mediated inhibition and improves NK cell antitumor activity against solid tumors. Front Immunol 14:1231916","journal-title":"Front Immunol"},{"key":"1778_CR101","doi-asserted-by":"publisher","DOI":"10.3390\/cells13050451","author":"A Maia","year":"2024","unstructured":"Maia A, Tarannum M, L\u00e9rias JR, Piccinelli S, Borrego LM, Maeurer M, Romee R, Castillo-Martin M (2024) Building a better defense: expanding and improving natural killer cells for adoptive cell therapy. Cells. https:\/\/doi.org\/10.3390\/cells13050451","journal-title":"Cells"},{"issue":"3","key":"1778_CR104","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1093\/stcltm\/szad087","volume":"13","author":"A Maia","year":"2024","unstructured":"Maia A, Tarannum M, Romee R (2024) Genetic manipulation approaches to enhance the clinical application of NK cell-based immunotherapy. Stem Cells Transl Med 13(3):230\u2013242","journal-title":"Stem Cells Transl Med"},{"key":"1778_CR88","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232314608","author":"M Market","year":"2022","unstructured":"Market M, Tennakoon G, Scaffidi M, Cook DP, Angka L, Ng J, de Tanese Souza C, Kennedy MA, Vanderhyden BC, Auer RC (2022) Preventing surgery-induced NK cell dysfunction using anti-TGF-\u03b2 immunotherapeutics. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms232314608","journal-title":"Int J Mol Sci"},{"issue":"9","key":"1778_CR53","doi-asserted-by":"publisher","first-page":"3427","DOI":"10.1111\/cas.14993","volume":"112","author":"F Marofi","year":"2021","unstructured":"Marofi F, Abdul-Rasheed OF, Rahman HS, Budi HS, Jalil AT, Yumashev AV, Hassanzadeh A, Yazdanifar M, Motavalli R, Chartrand MS (2021) CAR\u2010NK cell in cancer immunotherapy; a promising frontier. Cancer Sci 112(9):3427\u20133436","journal-title":"Cancer Sci"},{"issue":"9","key":"1778_CR49","doi-asserted-by":"publisher","first-page":"3427","DOI":"10.1111\/cas.14993","volume":"112","author":"F Marofi","year":"2021","unstructured":"Marofi F, Abdul-Rasheed OF, Rahman HS, Budi HS, Jalil AT, Yumashev AV, Hassanzadeh A, Yazdanifar M, Motavalli R, Chartrand MS et al (2021) CAR-NK cell in cancer immunotherapy; A promising frontier. Cancer Sci 112(9):3427\u20133436","journal-title":"Cancer Sci"},{"key":"1778_CR115","doi-asserted-by":"publisher","first-page":"673276","DOI":"10.3389\/fonc.2021.673276","volume":"11","author":"F Marofi","year":"2021","unstructured":"Marofi F, Al-Awad AS, Sulaiman Rahman H, Markov A, Abdelbasset WK, Ivanovna Enina Y, Mahmoodi M, Hassanzadeh A, Yazdanifar M, Stanley Chartrand M et al (2021) CAR-NK cell: A new paradigm in tumor immunotherapy. Front Oncol 11:673276","journal-title":"Front Oncol"},{"issue":"10","key":"1778_CR92","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.it.2022.08.004","volume":"43","author":"S Ma","year":"2022","unstructured":"Ma S, Caligiuri MA, Yu J (2022) Harnessing IL-15 signaling to potentiate NK cell-mediated cancer immunotherapy. Trends Immunol 43(10):833\u2013847","journal-title":"Trends Immunol"},{"key":"1778_CR116","doi-asserted-by":"publisher","first-page":"101073","DOI":"10.1016\/j.blre.2023.101073","volume":"60","author":"A Merino","year":"2023","unstructured":"Merino A, Maakaron J, Bachanova V (2023) Advances in NK cell therapy for hematologic malignancies: NK source, persistence and tumor targeting. Blood Rev 60:101073","journal-title":"Blood Rev"},{"key":"1778_CR64","doi-asserted-by":"crossref","unstructured":"Millan AJ, Allain V, Nayak I, Aguilar OA, Arakawa-Hoyt JS, Ureno G, Rothrock AG, Shemesh A, Eyquem J, Das J et al (2024) Spleen Tyrosine Kinase (SYK) negatively regulates ITAM-mediated human NK cell signaling and CD19-CAR NK cell efficacy. bioRxiv","DOI":"10.1101\/2024.07.09.602676"},{"issue":"3","key":"1778_CR91","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1093\/jimmun\/vkaf012","volume":"214","author":"AJ Millan","year":"2025","unstructured":"Millan AJ, Allain V, Nayak I, Libang JB, Quijada-Madrid LM, Arakawa-Hoyt JS, Ureno G, Rothrock AG, Shemesh A, Aguilar OA et al (2025) SYK negatively regulates ITAM-mediated human NK cell signaling and CD19-CAR NK cell efficacy. J Immunol 214(3):384\u2013398","journal-title":"J Immunol"},{"issue":"22","key":"1778_CR121","doi-asserted-by":"publisher","first-page":"16065","DOI":"10.3390\/ijms242216065","volume":"24","author":"T Mohammadian Gol","year":"2023","unstructured":"Mohammadian Gol T, Kim M, Sinn R, Ure\u00f1a-Bail\u00e9n G, Stegmeyer S, Gratz PG, Zahedipour F, Roig-Merino A, Antony JS, Mezger M (2023) CRISPR-Cas9-Based gene knockout of immune checkpoints in expanded NK cells. Int J Mol Sci 24(22):16065","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1778_CR112","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1186\/s12967-024-05534-8","volume":"22","author":"M Mohammad Taheri","year":"2024","unstructured":"Mohammad Taheri M, Javan F, Poudineh M, Athari SS (2024) Beyond CAR-T: the rise of CAR-NK cell therapy in asthma immunotherapy. J Transl Med 22(1):736","journal-title":"J Transl Med"},{"key":"1778_CR110","doi-asserted-by":"publisher","first-page":"1254821","DOI":"10.3389\/fimmu.2023.1254821","volume":"14","author":"N Murali Shankar","year":"2023","unstructured":"Murali Shankar N, Ortiz-Montero P, Kurzyukova A, Rackwitz W, K\u00fcnzel SR, Wels WS, Tonn T, Knopf F, Eitler J (2023) Preclinical assessment of CAR-NK cell-mediated killing efficacy and pharmacokinetics in a rapid zebrafish xenograft model of metastatic breast cancer. Front Immunol 14:1254821","journal-title":"Front Immunol"},{"issue":"2","key":"1778_CR44","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41571-020-0426-7","volume":"18","author":"JA Myers","year":"2021","unstructured":"Myers JA, Miller JS (2021) Exploring the NK cell platform for cancer immunotherapy. Nat Rev Clin Oncol 18(2):85\u2013100","journal-title":"Nat Rev Clin Oncol"},{"key":"1778_CR73","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-SITC2022.0413","volume-title":"413 genetic deletion of TIGIT enhances CAR-NK cell function in the solid tumor microenvironment","author":"I Navin","year":"2022","unstructured":"Navin I, Dysthe M, Baumgartner C, Parihar R (2022) 413 genetic deletion of TIGIT enhances CAR-NK cell function in the solid tumor microenvironment. BMJ Specialist Journals, In."},{"key":"1778_CR111","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.omto.2019.12.006","volume":"16","author":"YY Ng","year":"2020","unstructured":"Ng YY, Tay JCK, Wang S (2020) CXCR1 expression to improve anti-cancer efficacy of intravenously injected CAR-NK cells in mice with peritoneal xenografts. Mol Ther Oncolytics 16:75\u201385","journal-title":"Mol Ther Oncolytics"},{"issue":"6","key":"1778_CR11","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1159\/000541881","volume":"103","author":"R Novysedlak","year":"2025","unstructured":"Novysedlak R, Guney M, Al Khouri M, Bartolini R, Koumbas Foley L, Benesova I, Ozaniak A, Novak V, Vesely S, Pacas P (2025) The immune microenvironment in prostate cancer: a comprehensive review. Oncology 103(6):521\u2013545","journal-title":"Oncology"},{"issue":"1","key":"1778_CR32","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1042\/BST20200550","volume":"49","author":"M Pal","year":"2021","unstructured":"Pal M, Herold MJ (2021) CRISPR base editing applications for identifying cancer-driving mutations. Biochem Soc Trans 49(1):269\u2013280","journal-title":"Biochem Soc Trans"},{"issue":"1","key":"1778_CR5","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13046-022-02327-z","volume":"41","author":"K Pan","year":"2022","unstructured":"Pan K, Farrukh H, Chittepu V, Xu H, Pan CX, Zhu Z (2022) CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy. J Exp Clin Cancer Res 41(1):119","journal-title":"J Exp Clin Cancer Res"},{"issue":"10","key":"1778_CR4","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1038\/s41423-024-01207-0","volume":"21","author":"L Peng","year":"2024","unstructured":"Peng L, Sferruzza G, Yang L, Zhou L, Chen S (2024) CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors. Cell Mol Immunol 21(10):1089\u20131108","journal-title":"Cell Mol Immunol"},{"key":"1778_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-09087-8","author":"H Rafei","year":"2025","unstructured":"Rafei H, Basar R, Acharya S, Hsu Y-S, Liu P, Zhang D, Bohn T, Liang Q, Mohanty V, Upadhyay R (2025) CREM is a regulatory checkpoint of CAR and IL-15 signalling in NK cells. Nature. https:\/\/doi.org\/10.1038\/s41586-025-09087-8","journal-title":"Nature"},{"issue":"2","key":"1778_CR118","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1111\/bjh.19939","volume":"206","author":"H Rafei","year":"2025","unstructured":"Rafei H, Rezvani K (2025) Advances and challenges in chimeric antigen receptor-natural killer cell immunotherapy for cancer. Br J Haematol 206(2):443\u2013446","journal-title":"Br J Haematol"},{"issue":"5","key":"1778_CR30","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1007\/s10142-024-01455-3","volume":"24","author":"J Rajanathadurai","year":"2024","unstructured":"Rajanathadurai J, Perumal E, Sindya J (2024) Advances in targeting cancer epigenetics using CRISPR-dCas9 technology: a comprehensive review and future prospects. Funct Integr Genom 24(5):164","journal-title":"Funct Integr Genom"},{"issue":"2","key":"1778_CR56","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1158\/2326-6066.CIR-21-0218","volume":"10","author":"M Ramaswamy","year":"2022","unstructured":"Ramaswamy M, Kim T, Jones DC, Ghadially H, Mahmoud TI, Garcia A, Browne G, Zenonos Z, Puplampu-Dove Y, Riggs JM et al (2022) Immunomodulation of T- and NK-cell responses by a bispecific antibody targeting CD28 homolog and PD-L1. Cancer Immunol Res 10(2):200\u2013214","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"1778_CR107","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41392-022-01058-z","volume":"7","author":"GH Ran","year":"2022","unstructured":"Ran GH, Lin YQ, Tian L, Zhang T, Yan DM, Yu JH, Deng YC (2022) Natural killer cell homing and trafficking in tissues and tumors: from biology to application. Signal Transduct Target Therapy 7(1):205","journal-title":"Signal Transduct Target Therapy"},{"key":"1778_CR93","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.coi.2016.10.004","volume":"44","author":"J Rautela","year":"2017","unstructured":"Rautela J, Huntington ND (2017) IL-15 signaling in NK cell cancer immunotherapy. Curr Opin Immunol 44:1\u20136","journal-title":"Curr Opin Immunol"},{"issue":"5","key":"1778_CR19","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s10142-024-01435-7","volume":"24","author":"MK Razzaq","year":"2024","unstructured":"Razzaq MK, Babur MN, Awan MJA, Raza G, Mobeen M, Aslam A, Siddique KH (2024) Revolutionizing soybean genomics: how CRISPR and advanced sequencing are unlocking new potential. Funct Integr Genom 24(5):153","journal-title":"Funct Integr Genom"},{"issue":"4","key":"1778_CR85","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1038\/s41590-025-02103-z","volume":"26","author":"A Rea","year":"2025","unstructured":"Rea A, Santana-Hern\u00e1ndez S, Villanueva J, Sanvicente-Garc\u00eda M, Cabo M, Suarez-Olmos J, Quimis F, Qin M, Llorens E, Blasco-Benito S et al (2025) Enhancing human NK cell antitumor function by knocking out SMAD4 to counteract TGF\u03b2 and activin A suppression. Nat Immunol 26(4):582\u2013594","journal-title":"Nat Immunol"},{"issue":"1","key":"1778_CR128","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1186\/s13287-021-02406-6","volume":"12","author":"GM Robbins","year":"2021","unstructured":"Robbins GM, Wang M, Pomeroy EJ, Moriarity BS (2021) Nonviral genome engineering of natural killer cells. Stem Cell Res Ther 12(1):350","journal-title":"Stem Cell Res Ther"},{"issue":"4","key":"1778_CR57","doi-asserted-by":"publisher","first-page":"e010658","DOI":"10.1136\/jitc-2024-010658","volume":"13","author":"G Roex","year":"2025","unstructured":"Roex G, Gordon KS, Lion E, Birnbaum ME, Anguille S (2025) Expanding the CAR toolbox with high throughput screening strategies for CAR domain exploration: a comprehensive review. J Immunother Cancer 13(4):e010658","journal-title":"J Immunother Cancer"},{"key":"1778_CR79","unstructured":"Rojas E (2021) Using the CRISPR\/Cas9 system to understand the biology of natural killer cells and unleash their function in the tumour microenvironment"},{"issue":"8","key":"1778_CR54","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.jcyt.2022.02.006","volume":"24","author":"NT Schomer","year":"2022","unstructured":"Schomer NT, Jiang ZK, Lloyd MI, Klingemann H, Boissel L (2022) CCR7 expression in CD19 chimeric antigen receptor-engineered natural killer cells improves migration toward CCL19-expressing lymphoma cells and increases tumor control in mice with human lymphoma. Cytotherapy 24(8):827\u2013834","journal-title":"Cytotherapy"},{"issue":"3","key":"1778_CR62","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.ymthe.2025.01.024","volume":"33","author":"K Shankar","year":"2025","unstructured":"Shankar K, Zingler-Hoslet I, Tabima DM, Zima S, Shi L, Gimse K, Forsberg MH, Katta V, Davis SZ, Maldonado D et al (2025) Virus-free CRISPR knockin of a chimeric antigen receptor into KLRC1 generates potent GD2-specific natural killer cells. Mol Ther 33(3):1014\u20131030","journal-title":"Mol Ther"},{"issue":"1","key":"1778_CR35","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s11658-022-00336-6","volume":"27","author":"S Shojaei Baghini","year":"2022","unstructured":"Shojaei Baghini S, Gardanova ZR, Abadi SAH, Zaman BA, \u0130lhan A, Shomali N, Adili A, Moghaddar R, Yaseri AF (2022) CRISPR\/Cas9 application in cancer therapy: a pioneering genome editing tool. Cell Mol Biol Lett 27(1):35","journal-title":"Cell Mol Biol Lett"},{"key":"1778_CR113","doi-asserted-by":"publisher","first-page":"1226518","DOI":"10.3389\/fimmu.2023.1226518","volume":"14","author":"RN Silvestre","year":"2023","unstructured":"Silvestre RN, Eitler J, de Azevedo JTC, Tirapelle MC, Fantacini DMC, de Souza LEB, Swiech K, Covas DT, Calado RT, Montero PO et al (2023) Engineering NK-CAR.19 cells with the IL-15\/IL-15R\u03b1 complex improved proliferation and anti-tumor effect in vivo. Front Immunol 14:1226518","journal-title":"Front Immunol"},{"issue":"1","key":"1778_CR89","doi-asserted-by":"publisher","first-page":"5522","DOI":"10.1038\/s41467-021-25803-0","volume":"12","author":"H Song","year":"2021","unstructured":"Song H, Song J, Cheng M, Zheng M, Wang T, Tian S, Flavell RA, Zhu S, Li HB, Ding C et al (2021) METTL3-mediated m(6)A RNA methylation promotes the anti-tumour immunity of natural killer cells. Nat Commun 12(1):5522","journal-title":"Nat Commun"},{"key":"1778_CR36","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.addr.2020.04.010","volume":"168","author":"X Song","year":"2021","unstructured":"Song X, Liu C, Wang N, Huang H, He S, Gong C, Wei Y (2021) Delivery of CRISPR\/Cas systems for cancer gene therapy and immunotherapy. Adv Drug Deliv Rev 168:158\u2013180","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"1778_CR102","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1189\/jlb.1003488","volume":"76","author":"M Strengell","year":"2004","unstructured":"Strengell M, Julkunen I, Matikainen S (2004) IFN-alpha regulates IL-21 and IL-21R expression in human NK and T cells. J Leukoc Biol 76(2):416\u2013422","journal-title":"J Leukoc Biol"},{"issue":"1","key":"1778_CR90","doi-asserted-by":"publisher","first-page":"80","DOI":"10.18699\/VJ20.598","volume":"24","author":"V Subrakova","year":"2020","unstructured":"Subrakova V, Kulemzin S, Belovezhets T, Chikaev A, Chikaev N, Koval O, Gorchakov A, Taranin A (2020) Shp-2 gene knockout upregulates CAR-driven cytotoxicity of YT NK cells. Vavilov J Genet Breed 24(1):80","journal-title":"Vavilov J Genet Breed"},{"key":"1778_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41551-025-01371-2","volume":"9","author":"K Tang","year":"2025","unstructured":"Tang K, Zhou L, Tian X, Fang S-Y, Vandenbulcke E, Du A, Shen J, Cao H, Zhou J, Chen K (2025) Cas12a-knock-in mice for multiplexed genome editing, disease modelling and immune-cell engineering. Nat Biomed Eng 9:1","journal-title":"Nat Biomed Eng"},{"issue":"2","key":"1778_CR68","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1158\/2159-8290.CD-23-0519","volume":"14","author":"BC Taylor","year":"2024","unstructured":"Taylor BC, Sun X, Gonzalez-Ericsson PI, Sanchez V, Sanders ME, Wescott EC, Opalenik SR, Hanna A, Chou ST, Van Kaer L et al (2024) NKG2A is a therapeutic vulnerability in immunotherapy resistant MHC-I heterogeneous Triple-Negative breast cancer. Cancer Discov 14(2):290\u2013307","journal-title":"Cancer Discov"},{"issue":"21","key":"1778_CR77","doi-asserted-by":"publisher","first-page":"12828","DOI":"10.3390\/ijms232112828","volume":"23","author":"G Ure\u00f1a-Bail\u00e9n","year":"2022","unstructured":"Ure\u00f1a-Bail\u00e9n G, Dobrowolski J-M, Hou Y, Dirlam A, Roig-Merino A, Schleicher S, Atar D, Seitz C, Feucht J, Antony JS (2022) Preclinical evaluation of CRISPR-edited CAR-NK-92 cells for off-the-shelf treatment of AML and B-ALL. Int J Mol Sci 23(21):12828","journal-title":"Int J Mol Sci"},{"key":"1778_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232112828","author":"G Ure\u00f1a-Bail\u00e9n","year":"2022","unstructured":"Ure\u00f1a-Bail\u00e9n G, Dobrowolski JM, Hou Y, Dirlam A, Roig-Merino A, Schleicher S, Atar D, Seitz C, Feucht J, Antony JS et al (2022) Preclinical evaluation of CRISPR-edited CAR-NK-92 cells for off-the-shelf treatment of AML and B-ALL. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms232112828","journal-title":"Int J Mol Sci"},{"key":"1778_CR94","doi-asserted-by":"publisher","first-page":"112156","DOI":"10.1016\/j.intimp.2024.112156","volume":"133","author":"S Vahidi","year":"2024","unstructured":"Vahidi S, Zabeti Touchaei A, Samadani AA (2024) IL-15 as a key regulator in NK cell-mediated immunotherapy for cancer: from bench to bedside. Int Immunopharmacol 133:112156","journal-title":"Int Immunopharmacol"},{"issue":"415","key":"1778_CR83","doi-asserted-by":"publisher","first-page":"ra19","DOI":"10.1126\/scisignal.aad1884","volume":"9","author":"S Viel","year":"2016","unstructured":"Viel S, Mar\u00e7ais A, Guimaraes FS, Loftus R, Rabilloud J, Grau M, Degouve S, Djebali S, Sanlaville A, Charrier E et al (2016) TGF-\u03b2 inhibits the activation and functions of NK cells by repressing the mTOR pathway. Sci Signal 9(415):ra19","journal-title":"Sci Signal"},{"issue":"6","key":"1778_CR37","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/s41580-023-00697-6","volume":"25","author":"L Villiger","year":"2024","unstructured":"Villiger L, Joung J, Koblan L, Weissman J, Abudayyeh OO, Gootenberg JS (2024) CRISPR technologies for genome, epigenome and transcriptome editing. Nat Rev Mol Cell Biol 25(6):464\u2013487","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1778_CR95","doi-asserted-by":"publisher","first-page":"868","DOI":"10.3389\/fimmu.2020.00868","volume":"11","author":"TA Waldmann","year":"2020","unstructured":"Waldmann TA, Dubois S, Miljkovic MD, Conlon KC (2020) IL-15 in the combination immunotherapy of cancer. Front Immunol 11:868","journal-title":"Front Immunol"},{"issue":"5","key":"1778_CR40","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1158\/2159-8290.CD-20-1243","volume":"11","author":"D Wang","year":"2021","unstructured":"Wang D, Prager BC, Gimple RC, Aguilar B, Alizadeh D, Tang H, Lv D, Starr R, Brito A, Wu Q et al (2021) CRISPR screening of CAR T cells and cancer stem cells reveals critical dependencies for Cell-Based therapies. Cancer Discov 11(5):1192\u20131211","journal-title":"Cancer Discov"},{"issue":"26","key":"1778_CR84","doi-asserted-by":"publisher","first-page":"2788","DOI":"10.1182\/blood.2022015474","volume":"140","author":"D Wang","year":"2022","unstructured":"Wang D, Sun Z, Zhu X, Zheng X, Zhou Y, Lu Y, Yan P, Wang H, Liu H, Jin J et al (2022) GARP-mediated active TGF-\u03b21 induces bone marrow NK cell dysfunction in AML patients with early relapse post-allo-HSCT. Blood 140(26):2788\u20132804","journal-title":"Blood"},{"key":"1778_CR45","doi-asserted-by":"publisher","first-page":"109193","DOI":"10.1016\/j.intimp.2022.109193","volume":"112","author":"J Wang","year":"2022","unstructured":"Wang J, Liu X, Jin T, Cao Y, Tian Y, Xu F (2022) NK cell immunometabolism as target for liver cancer therapy. Int Immunopharmacol 112:109193","journal-title":"Int Immunopharmacol"},{"key":"1778_CR120","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009560","author":"M Wang","year":"2025","unstructured":"Wang M, Krueger JB, Gilkey AK, Stelljes EM, Kluesner MG, Pomeroy EJ, Skeate JG, Slipek NJ, Lahr WS, Claudio V\u00e1zquez PN (2025) Precision enhancement of CAR-NK cells through non-viral engineering and highly multiplexed base editing. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2024-009560","journal-title":"J Immunother Cancer"},{"issue":"5","key":"1778_CR127","doi-asserted-by":"publisher","first-page":"e009560","DOI":"10.1136\/jitc-2024-009560","volume":"13","author":"M Wang","year":"2025","unstructured":"Wang M, Krueger JB, Gilkey AK, Stelljes EM, Kluesner MG, Pomeroy EJ, Skeate JG, Slipek NJ, Lahr WS, V\u00e1zquez PNC (2025) Precision enhancement of CAR-NK cells through non-viral engineering and highly multiplexed base editing. J Immunother Cancer 13(5):e009560","journal-title":"J Immunother Cancer"},{"issue":"2","key":"1778_CR59","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/s41419-024-06526-8","volume":"15","author":"L Wu","year":"2024","unstructured":"Wu L, Zhou Z, Yu Y, Cheng C, Zhou S, Yan Y, Yu B, Zhang Y, Liu Z (2024) Phosphorylation-dependent deubiquitinase OTUD3 regulates YY1 stability and promotes colorectal cancer progression. Cell Death Dis 15(2):137","journal-title":"Cell Death Dis"},{"key":"1778_CR8","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.omto.2022.10.011","volume":"27","author":"X Wu","year":"2022","unstructured":"Wu X, Matosevic S (2022) Gene-edited and CAR-NK cells: opportunities and challenges with engineering of NK cells for immunotherapy. Mol Ther Oncolytics 27:224\u2013238","journal-title":"Mol Ther Oncolytics"},{"key":"1778_CR50","doi-asserted-by":"publisher","first-page":"102975","DOI":"10.1016\/j.ebiom.2020.102975","volume":"59","author":"G Xie","year":"2020","unstructured":"Xie G, Dong H, Liang Y, Ham JD, Rizwan R, Chen J (2020) CAR-NK cells: a promising cellular immunotherapy for cancer. EBioMedicine 59:102975","journal-title":"EBioMedicine"},{"key":"1778_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102975","author":"G Xie","year":"2020","unstructured":"Xie G, Dong H, Liang Y, Ham JD, Rizwan R, Chen J (2020) CAR-NK cells: a promising cellular immunotherapy for cancer. EBioMedicine. https:\/\/doi.org\/10.1016\/j.ebiom.2020.102975","journal-title":"EBioMedicine"},{"key":"1778_CR124","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.imlet.2022.09.004","volume":"250","author":"Z Yang","year":"2022","unstructured":"Yang Z, Wu H, Lin Q, Wang X, Kang S (2022) Lymphopenic condition enhanced the antitumor immunity of PD-1-knockout T cells mediated by CRISPR\/Cas9 system in malignant melanoma. Immunol Lett 250:15\u201322","journal-title":"Immunol Lett"},{"issue":"4","key":"1778_CR41","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.cmet.2022.02.009","volume":"34","author":"L Ye","year":"2022","unstructured":"Ye L, Park JJ, Peng L, Yang Q, Chow RD, Dong MB, Lam SZ, Guo J, Tang E, Zhang Y et al (2022) A genome-scale gain-of-function CRISPR screen in CD8 T cells identifies proline metabolism as a means to enhance CAR-T therapy. Cell Metab 34(4):595\u2013614e514","journal-title":"Cell Metab"},{"issue":"6Supplement","key":"1778_CR126","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1158\/1538-7445.AM2024-1328","volume":"84","author":"H Ying","year":"2024","unstructured":"Ying H, Yao C, Fang C, Li G, Wang L, Zhou Y, Gong C, Li J, Wang Y, Fan W (2024) AccuBaseTM (ceBE), a second-generation high-fidelity base editor, can proficiently modify genes in a human primary NK cells with minimizing off-target effect. Cancer Res 84(6Supplement):1328\u20131328","journal-title":"Cancer Res"},{"issue":"1","key":"1778_CR106","doi-asserted-by":"publisher","first-page":"200777","DOI":"10.1016\/j.omton.2024.200777","volume":"32","author":"JH Yoon","year":"2024","unstructured":"Yoon JH, Yoon HN, Kang HJ, Yoo H, Choi MJ, Chung JY, Seo M, Kim M, Lim SO, Kim YJ et al (2024) Empowering pancreatic tumor homing with augmented anti-tumor potency of CXCR2-tethered CAR-NK cells. Mol Ther Oncol 32(1):200777","journal-title":"Mol Ther Oncol"},{"issue":"2","key":"1778_CR81","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.stem.2020.05.008","volume":"27","author":"H Zhu","year":"2020","unstructured":"Zhu H, Blum RH, Bernareggi D, Ask EH, Wu Z, Hoel HJ, Meng Z, Wu C, Guan K-L, Malmberg K-J (2020) Metabolic reprograming via deletion of CISH in human iPSC-derived NK cells promotes in vivo persistence and enhances anti-tumor activity. Cell Stem Cell 27(2):224\u2013237 e226","journal-title":"Cell Stem Cell"},{"issue":"1","key":"1778_CR6","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1186\/s12943-024-02151-3","volume":"23","author":"X Zhu","year":"2024","unstructured":"Zhu X, Xue J, Jiang H, Xue D (2024) CAR-NK cells for gastrointestinal cancer immunotherapy: from bench to bedside. Mol Cancer 23(1):237","journal-title":"Mol Cancer"}],"container-title":["Functional & Integrative Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10142-025-01778-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10142-025-01778-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10142-025-01778-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T07:02:34Z","timestamp":1765954954000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10142-025-01778-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,17]]},"references-count":128,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["1778"],"URL":"https:\/\/doi.org\/10.1007\/s10142-025-01778-9","relation":{},"ISSN":["1438-793X","1438-7948"],"issn-type":[{"type":"print","value":"1438-793X"},{"type":"electronic","value":"1438-7948"}],"subject":[],"published":{"date-parts":[[2025,12,17]]},"assertion":[{"value":"12 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4"}}